A Hecker1, M Reichert2, C J Reuß3, T Schmoch3, J G Riedel2, E Schneck4, W Padberg2, M A Weigand3, M Hecker5. 1. Department of General and Thoracic Surgery, University Hospital of Giessen, Rudolf-Buchheim-Street 7, 35392, Gießen, Germany. Andreas.Hecker@chiru.med.uni-giessen.de. 2. Department of General and Thoracic Surgery, University Hospital of Giessen, Rudolf-Buchheim-Street 7, 35392, Gießen, Germany. 3. Department of Anesthesiology, University Hospital of Heidelberg, Heidelberg, Germany. 4. Department of Anesthesiology, University Hospital of Giessen, Giessen, Germany. 5. Medical Clinic II, University Hospital of Giessen, Giessen, Germany.
Abstract
PURPOSE: The abdomen is the second most common source of sepsis and is associated with unacceptably high morbidity and mortality. Recently, the essential definitions of sepsis and septic shock were updated (Third International Consensus Definitions for Sepsis and Septic Shock, Sepsis-3) and modified. The purpose of this review is to provide an overview of the changes introduced by Sepsis-3 and the current state of the art regarding the treatment of abdominal sepsis. RESULTS: While Sepsis-1/2 focused on detecting systemic inflammation as a response to infection, Sepsis-3 defines sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection. The Surviving Sepsis Campaign (SSC) guideline, which was updated in 2016, recommends rapid diagnosis and initiating standardized therapy. New diagnostic tools, the establishment of antibiotic stewardship programs, and a host of new-generation antibiotics are new landmark changes in the sepsis literature of the last few years. Although the "old" surgical source control consisting of debridement, removal of infected devices, drainage of purulent cavities, and decompression of the abdominal cavity is the gold standard of surgical care, the timing of gastrointestinal reconstruction and closure of the abdominal cavity ("damage control surgery") are discussed intensively in the literature. The SSC guidelines provide evidence-based sepsis therapy. Nevertheless, treating critically ill intensive care patients requires individualized, continuous daily re-evaluation and flexible therapeutic strategies, which can be best discussed in the interdisciplinary rounds of experienced surgeons and intensive care medicals.
PURPOSE: The abdomen is the second most common source of sepsis and is associated with unacceptably high morbidity and mortality. Recently, the essential definitions of sepsis and septic shock were updated (Third International Consensus Definitions for Sepsis and Septic Shock, Sepsis-3) and modified. The purpose of this review is to provide an overview of the changes introduced by Sepsis-3 and the current state of the art regarding the treatment of abdominal sepsis. RESULTS: While Sepsis-1/2 focused on detecting systemic inflammation as a response to infection, Sepsis-3 defines sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection. The Surviving Sepsis Campaign (SSC) guideline, which was updated in 2016, recommends rapid diagnosis and initiating standardized therapy. New diagnostic tools, the establishment of antibiotic stewardship programs, and a host of new-generation antibiotics are new landmark changes in the sepsis literature of the last few years. Although the "old" surgical source control consisting of debridement, removal of infected devices, drainage of purulent cavities, and decompression of the abdominal cavity is the gold standard of surgical care, the timing of gastrointestinal reconstruction and closure of the abdominal cavity ("damage control surgery") are discussed intensively in the literature. The SSC guidelines provide evidence-based sepsis therapy. Nevertheless, treating critically ill intensive care patients requires individualized, continuous daily re-evaluation and flexible therapeutic strategies, which can be best discussed in the interdisciplinary rounds of experienced surgeons and intensive care medicals.
Authors: Christen E Salyer; Christian B Bergmann; Richard S Hotchkiss; Peter A Crisologo; Charles C Caldwell Journal: J Surg Res Date: 2022-02-05 Impact factor: 2.417
Authors: Bong-Sung Kim; Pathricia V Tilstam; Kevin Arnke; Lin Leng; Tim Ruhl; Marta Piecychna; Wibke Schulte; Maor Sauler; Florian S Frueh; Gabriele Storti; Nicole Lindenblatt; Pietro Giovanoli; Norbert Pallua; Jürgen Bernhagen; Richard Bucala Journal: FASEB J Date: 2020-01-21 Impact factor: 5.191
Authors: S Dubler; M Lenz; S Zimmermann; D C Richter; K H Weiss; A Mehrabi; M Mieth; T Bruckner; M A Weigand; T Brenner; A Heininger Journal: Antimicrob Resist Infect Control Date: 2020-01-31 Impact factor: 4.887
Authors: Elisabeth Gasser; Daniel Rezaie; Johanna Gius; Andreas Lorenz; Philipp Gehwolf; Alexander Perathoner; Dietmar Öfner; Reinhold Kafka-Ritsch Journal: Front Surg Date: 2021-06-04
Authors: A I Gutiérrez-Falcón; A M Ramos-Nuez; A Espinosa de Los Monteros Y Zayas; D F Padilla Castillo; M Isabel García-Laorden; F J Chamizo-López; F Real Valcárcel; F Artilles Campelo; A Bordes Benítez; P Nogueira Salgueiro; C Domínguez Cabrera; J C Rivero-Vera; J M González-Martín; J Martín Caballero; R Frías-Beneyto; Jesús Villar; J L Martín-Barrasa Journal: Probiotics Antimicrob Proteins Date: 2021-03-13 Impact factor: 4.609